Skip to main content
. 2019 Oct;7(20):524. doi: 10.21037/atm.2019.10.15

Table 3. Second-line therapy after disease progression.

Therapy Maintenance therapy (n=47), n (%) No maintenance therapy (n=29), n (%)
EGFR-TKI 14 (29.8) 2 (6.9)
Crizotinib 3 (6.4) 1 (3.4)
Docetaxel-based therapy 15 (31.9) 9 (31.0)
Radiotherapy 3 (6.4) 3 (10.3)
Other treatment 6 (12.8) 4 (13.8)
No treatment 6 (12.8) 10 (34.5)

EGFR-TKI, epidermal growth factor receptor-tyrosine kinase inhibitor.